Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Subscribe To Our Newsletter & Stay Updated
